Aurobindo Pharma - Q4FY13 Result Preview - Angel Broking

Aurobindo Pharmaceuticals is expected to post a net sales growth of 5.3% yoy. The margin is likely to expand to 18.3% vs 10.2% in the corresponding period of last year, which will lead to a net profit of Rs. 194.2cr vs a net profit of Rs. 108.5cr, respectively.

We maintain our buy with a target of 264.

Source : Equity Bulls

Keywords